Immunohistochemistry (IHC) Market

Immunohistochemistry (IHC) Market by Product (Antibodies, Reagents, Equipment, Kits), Application (Diagnostics (Cancer, Infectious, Autoimmune Diseases), Research, Forensic), End Users (Diagnostic laboratories, Research Institute) - Global Forecast to 2028

Report Code: BT 4780 Jun, 2023, by marketsandmarkets.com

The global immunohistochemistry market in terms of revenue was estimated to be worth $3.2 billion in 2023 and is poised to reach $4.7 billion by 2028, growing at a CAGR of 7.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Factors such as burgeoning geriatric population and growing prevalence of cancer diseases, technological advancements in IHC providing diagnostic accuracy and precision, the availability of reimbursement for IHC tests, and adoption of digital pathology are the major factors driving the growth of this market. However, the presence of alternative technologies and high degree of consolidation is expected to restrain the market’s growth during the forecast period. The stringent regulatory requirements for IVD equipments and lack of standardization may also pose a challenge to the growth of this market to a certain extent.

Immunohistochemistry Market

To know about the assumptions considered for the study, Request for Free Sample Report

Immunohistochemistry Market

Immunohistochemistry Market Dynamics

Driver: Adoption of Digital Pathology Fueling Market Growth

Digital pathology systems are increasingly being utilized by healthcare professionals across the globe due to the ongoing trend of automation of diagnostic laboratory processes across major healthcare markets. Digital immunohistochemistry (IHC) integrates traditional IHC staining with digital imaging and analysis tools, facilitating the conversion of stained tissue slides into electronic images that can be remotely accessed, analyzed, and stored, eliminating the reliance on physical slides and enabling efficient collaboration among pathologists and researchers. The advantages of digital pathology application in IHC is that it eliminates physical slide handling and storage, facilitates remote collaboration among pathologists for case sharing and second opinions, enables objective and standardized quantitative analysis of staining, and allows efficient archiving and integration of digital images with other data for comprehensive analysis and research. The major players offering digital IHC are F. Hoffmann-La Roche AG, Leica Biosystems (Danaher Corporation), and Agilent Technologies.

Governments and industry players across the globe are focusing on various strategies in the field of digital pathology to provide a highly advanced, fast, and accurate diagnosis. Listed below are some key developments in this regard:

  • In January 2023, Agilent Technologies, Inc. announced a partnership with Akoya Biosciences, Inc. to develop multiplex-immunohistochemistry diagnostic solutions and commercialize workflow solutions for multiplex assays. This partnership will deliver an end-to-end multiplex IHC solution for biomarker clinical research enabled by digital pathology.
  • In June 2022, Roche launched VENTANA DP 600 a slide scanner, a digital pathology systems for developing digital images of stained tissue samples.

Restraint: Availability of Alternative Technologies

Although Immunohistochemistry is a widely used technology in pathology for identification of proteins or antigens in tissue samples. There is an availability of alternative advanced technologies that are being used for diagnostic and research purposes some of these are listed below:

  • RNA sequencing: RNA sequencing, also known as transcriptome sequencing, is an alternative method to immunohistochemistry (IHC) for analyzing gene expression. It involves determining the sequence and abundance of RNA molecules present in the cell. By sequencing the RNA, researchers can obtain data known as the transcriptome, which provides insights into the activity of all genes within the cell. RNA sequencing allows for a comprehensive assessment of gene expression profiles without the limitations associated with IHC.
  • Next Generation Sequencing: NGS is a powerful technology that enables high-throughput sequencing of DNA, allowing for detailed analysis of the genetic composition and expression patterns in tissue samples. It serves as a valuable tool for molecular profiling and the identification of genetic alterations in these samples. Thus, NGS is being considered as an alternative for IHC.
  • FISH: FISH is used to identify and visualize specific DNA sequences or chromosomal abnormalities within cells. FISH is particularly valuable in confirming DNA amplifications at the gene level when immunohistochemistry (IHC) results are inconclusive or equivocal. While IHC detects protein expression, it may not provide a direct measurement of gene copy number or gene amplification. In cases where IHC results raise suspicions of gene amplification, FISH is employed to verify and quantify the actual gene copy number. In a study survey by, the College of American Pathologists it was reported that FISH was more precise and accurate than IHC.

Such alternative techniques prove to be a restraint to the IHC market.

Opportunity: Growing significance of companion diagnostics

Companion diagnostics include tests or assays intended to assist healthcare providers in making treatment decisions for patients based on the best response to therapy. The co-development of companion diagnostics with therapeutic products has the potential to significantly alter the drug development process and commercialize drug candidates by yielding safer drugs with enhanced therapeutic efficacy quickly and cost-effectively. With an increase in the demand for high-priced specialist therapies and safer drugs, the market for companion diagnostics has a high growth potential. The growing importance of companion diagnostics is also providing growth opportunities for the diagnostics segment and, in turn, the IHC market. Recently, In October 2022, Roche received approval by US FDA for first IHC based companion diagnostic for PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify metastatic breast cancer patients with low HER2 expression for whom Enhertu (fam-trastuzumab deruxtecan-nxki). Pharmaceutical companies are increasingly collaborating with diagnostic companies to make safer and more effective drugs. For instance, in January 2023, Thermo partnered with AstraZeneca to Develop Solid Tissue and Blood-Based Companion Diagnostic Test for Tagrisso. Also, in January 2020, Amgen entered into strategic collaborations with Guardant Health, Inc. (US) and QIAGEN (Germany) to develop blood- and tissue e-based companion diagnostics (CDx), for investigational cancer treatment AMG 510. Such development for companion diagnostics and the integration of companion diagnostics with IHC is facilitating personalized medicine, supporting drug development and approval processes, expanding market potential, improves patient outcomes, encouraging research collaboration, and providing growth opportunities for Immunohistochemistry Market.

Challenge: Stringent regulatory requirements

The current FDA approval process for tissue diagnostic instruments and consumables is very lengthy and complex. This is a major challenge faced by companies in terms of launching new and innovative products. Some products used for tissue diagnostics belong to Class III (under FDA classification) and require Premarket Approval (PMA) before they can be successfully marketed. PMA evaluates the safety and effectiveness of products and is considered the most rigorous marketing application. Similarly, in April 2017, the European Parliament and the Council of the European Union issued the new Regulation (EU) 2017/746 for in vitro diagnostic medical devices. This resolution will replace the existing In Vitro Diagnostic Devices Directive (IVDD) 98/79/EC, and companies will have 5 years to comply with the new regulations (which are more complex and stringent). Considering these stringent regulations, market players in the Immunohistochemistry will find it challenging to align their processes with stringent requirements, which could temporarily impact the time to market for new products, especially in the US and Europe.

Immunohistochemistry Market Ecosystem

The market ecosystem comprises of product providers and end users such as Hospital and Diagnostic Centers, Academic and Research Institutes, and Other end users such as Pharmaceutical & Biotechnology companies, and CROs. The supplier of IHC products develop, manufacture, and distribute IHC products such as antibodies, reagents, kits, and instruments for applications such as diagnosis, and research. Overall, the market ecosystem for IHC is a complex and dynamic network of different players, all working together to advance diagnosis, treatment, and research for different diseases.

Immunohistochemistry Market Ecosystem

The prominent players of this market are F. Hoffmann-LA-Roche AG (Switzerland), Danaher Corporation (US), Agilent Technologies Inc. (US), Merck KGAA (Germany), Bio-Rad Laboratories Inc.(US), Eagle Biosciences Inc. (US), Biocare Medical LLC. (US), Elabscience Biotechnology Inc. (China), Bio-Genex Laboratories (US), Diagnostic Biosystem (US), Histo-Line Laboratories (Italy), Rockland Immunochemicals Inc. (US), Genemed Biotechnologies Inc.(US), Candoor Bioscience GMBH (Germany), Bio-Techne Corporation (US), Abcam PLC (UK), Becton, Dickinson and Company (US), Perkinelmer Inc. (US), Takara Bio, Inc. (Japan), Thermo Fisher Scientific Inc. (US), PHC Holdings Corporation (Japan), Cell Signaling Technology Inc. (US), Bio SB Inc. (US), Miltenyi Biotech (Germany), Sakura finetek Japan Co., Ltd.(Japan), Enzo Biochem, Inc.(US), and Origene Technologies Inc.(US).

Based on application, diagnostic segment accounted for the largest market share of the Immunohistochemistry market

Based on application, the IHC market is segmented into diagnostic, research, and forensic applications. The Diagnostic application segment dominated this market in 2022 and is estimated to register the highest growth during the forecast period. The growth of this segment is majorly attributed to factors such as the increasing prevalence of chronic diseases, such as cancer, neurological disorders, and autoimmune conditions, has also fueled the demand for diagnostic applications of IHC. Also, the advantages of development of IHC technology over traditional techniques that utilize special enzyme staining techniques that identifies only a limited number of proteins, tissue structures, and enzymes. Due to such reasons IHC has become a crucial technique and is being widely used for medical research as.

Based on product, antibodies segment accounted for the largest market share of the Immunohistochemistry market

Based on product, the IHC market is segmented into antibodies, reagents, equipment, and kits. In 2022, the antibodies segment accounted for the largest share of the IHC market. The large market share of Antibodies product segment can be attributed to the advancements in antibody development and manufacturing techniques which have significantly enhanced the product quality, sensitivity and specificity for application in IHC. There are also multiple product launches and approvals in this segment promoting market growth.

Based on end users, hospitals & diagnostic laboratories segment accounted for the largest market share of the Immunohistochemistry market

Based on end user, the IHC market is segmented into hospitals & diagnostic laboratories, academic & research institutes, and other end users. The hospitals & diagnostic laboratories segment accounted for the largest share of the IHC market in 2022. Factors such as the rising number of in-house diagnostic procedures in hospitals, the growing trend of establishing in-house diagnostic capabilities in hospitals to provide time-bound and affordable patient services, availability of reimbursement, significant increase in the volume of diagnostic testing performed in hospitals and diagnostic labs due to the rising incidence of diseases such as cancer, autoimmune disorders, and infectious diseases.

The Asia Pacific market is projected to register the fastest growth rate for the Immunohistochemistry market

The global immunohistochemistry market is broadly segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. APAC is expected to register the fastest growth rate during the forecast period owing to several factors, including growing disposable income, increasing demand for quality medical care, and expanding investments by pharmaceutical and biopharmaceutical companies. The rising prevalence of chronic ailments, rapidly increasing geriatric population, growing academic and government investments in diagnostic research, and the presence of many market players are the other major factors driving the growth of the immunohistochemistry market in APAC.

Immunohistochemistry Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The Immunohistochemistry market is dominated by a few globally established players such as F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US), among others. Major focus was given to the deals, expansions, and new product launches due to the changing requirements of end users across the world.

Immunohistochemistry Market Report Scope

Report Metric

Details

Market Revenue in 2023

$3.2 billion

Projected Revenue by 2028

$4.7 billion

Revenue Rate

Poised to grow at a CAGR of 7.4%

Market Driver

Adoption of Digital Pathology Fueling Market Growth

Market Opportunity

Growing significance of companion diagnostics

This study categorizes the global immunohistochemistry market to forecast revenue and analyze trends in each of the following submarkets

By Product

  • Antibodies
    • Primary antibodies
    • Secondary antibodies
  • Reagents
    • Histological Stains
    • Blocking Sera and Reagents
    • Chromogenic Substrates
    • Fixation Reagents
    • Organic Solvents
    • Proteolytic Enzymes
    • Diluents
    • Other Reagents (antigen retrieval solutions, stabilizers, controls, and mounting solutions)
  • Equipment
    • Slide-staining Systems
    • Tissue Processing Systems
    • Slide Scanners
    • Other Equipment (automated cover slippers, visualization equipment, microtomes, paraffin dispensers, slide labelers, and tissue microarrays)
  • Kits
    • IHC Kits for Human tissue
    • IHC Kits for Animal tissue

By Application

  • Diagnostic applications
    • Cancer
    • Infectious diseases
    • Autoimmune diseases
    • Nephrological diseases
    • Neurological diseases
    • Other diseases (ophthalmic, cardiovascular, dermatological, and dental diseases)
  • Research applications
    • Drug development and Testing
    • Other research applications (stem cell research and developmental biology)
  • Forensic applications

By End user

  • Hospitals & Diagnostic Laboratories
  • Academic & research Institutes
  • Other end users (CROs, pharma & biopharma companies, and forensic laboratories)

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • Japan
    • China
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Rest of the World (RoW)
    • Latin America
    • Middle East and Africa

Recent Developments

  • In February 2023, F. Hoffman-La Roche AG (Switzerland) launched IDH1 R132H (MRQ-67) Rabbit Monoclonal Antibody and the ATRX Rabbit Polyclonal Antibody for use in BenchMark series of instrument for detection of brain cancer.
  • In October 2022, F. Hoffman-La Roche AG (Switzerland) received US FDA approval for PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody use as companion diagnostic test to identify metastatic breast cancer patients with low HER2 expression.
  • In April 2023, Danaher Corporation (US), subsidiary Leica Biosystems received FDA clearance for BOND MMR Antibody Panel, for detection of colorectal cancer.
  • In November 2022, Danaher Corporation (US), subsidiary Leica Biosystems Nussloch GmbH acquired Cell IDx, Inc. an immunodiagnostic company offering chromogenic and fluorescent multiplex IHC biomarker profiling products.
  • In January 2023, Agilent Technologies, Inc. (US) signed a partnership deal with Akoya Biosciences for developing chromogenic and immunofluorescent multiplex assays. These assays will be used for immunohistochemistry diagnostic solutions.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 47)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
                    TABLE 1 IMMUNOHISTOCHEMISTRY MARKET SHARE: INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 IMMUNOHISTOCHEMISTRY MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
           1.7.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 53)
    2.1 RESEARCH DATA 
          FIGURE 2 IHC MARKET: RESEARCH DESIGN METHODOLOGY
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 IHC MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET ESTIMATION METHODOLOGY 
          FIGURE 4 IHC MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
          FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 MARKET GROWTH RATE PROJECTIONS 
          FIGURE 7 IHC MARKET (SUPPLY SIDE): CAGR PROJECTIONS
                    FIGURE 8 IHC MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
           2.3.1 DATA TRIANGULATION
                    FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS 
    2.5 RISK ANALYSIS 
    2.6 RECESSION IMPACT 
          TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
          TABLE 3 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 4 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 65)
    FIGURE 10 IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT,  2023 VS. 2028 (USD MILLION)
    FIGURE 11 IMMUNOHISTOCHEMISTRY MARKET SHARE, BY APPLICATION, 2022
    FIGURE 12 IMMUNOHISTOCHEMISTRY MARKET FORECAST, BY END USER, 2023 VS. 2028
    FIGURE 13 IMMUNOHISTOCHEMISTRY MARKET TRENDS: REGIONAL SNAPSHOT
 
4 PREMIUM INSIGHTS (Page No. - 68)
    4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW 
          FIGURE 14 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SHARE,  BY END USER AND COUNTRY (2022) 
          FIGURE 15 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC IHC MARKET IN 2022
    4.3 IMMUNOHISTOCHEMISTRY MARKET GROWTH FOR ANTIBODIES, BY TYPE 
          FIGURE 16 PRIMARY ANTIBODIES SEGMENT TO LEAD IHC ANTIBODIES MARKET DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 71)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 17 IHC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
          TABLE 5 IHC MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Rising geriatric population and growing prevalence of cancer
                                TABLE 6 ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION,  BY REGION (2022–2050)
                                FIGURE 18 CANCER INCIDENCE, BY REGION AND TYPE OF CANCER, 2020
                    5.2.1.2 Technological advancements in IHC
                    5.2.1.3 Availability of reimbursements for IHC tests
                                TABLE 7 CPT CODES FOR IHC PROCEDURES
                    5.2.1.4 Adoption of digital pathology
           5.2.2 RESTRAINTS
                    5.2.2.1 Availability of alternative technologies
                    5.2.2.2 High degree of consolidation
                                TABLE 8 MAJOR ACQUISITIONS IN MARKET, 2020–2023
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing demand for personalized medicine
                                FIGURE 19 GROWTH OF PERSONALIZED MEDICINES APPROVED BY FDA, 2015–2022
                    5.2.3.2 Growing significance of companion diagnostics
                    5.2.3.3 Growth opportunities in emerging countries
                    5.2.3.4 Application of artificial intelligence in IHC
           5.2.4 CHALLENGES
                    5.2.4.1 Product failures and recalls
                    5.2.4.2 Stringent regulatory requirements
                    5.2.4.3 Lack of standardization
    5.3 ELEMENTS OF UNCERTAINTY IN IHC MARKET 
          FIGURE 20 IHC MARKET: SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH
    5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 21 REVENUE SHIFT & NEW REVENUE POCKETS FOR IHC PROVIDERS
    5.5 PRICING ANALYSIS 
          TABLE 9 AVERAGE SELLING PRICE OF SOME IHC EQUIPMENT, REAGENTS, AND KITS (2022)
           5.5.1 AVERAGE SELLING PRICE TRENDS
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 22 VALUE CHAIN ANALYSIS OF IHC MARKET: RAW MATERIAL AND MANUFACTURING PHASE TO CONTRIBUTE MAXIMUM VALUE
           5.6.1 RESEARCH AND PRODUCT DEVELOPMENT
    5.7 ECOSYSTEM ANALYSIS 
          FIGURE 23 IHC MARKET: ECOSYSTEM ANALYSIS
          TABLE 10 SUPPLY CHAIN ECOSYSTEM
    5.8 TECHNOLOGY ANALYSIS 
    5.9 PATENT ANALYSIS 
          FIGURE 24 IHC MARKET: PATENT ANALYSIS, 2014–2023
          TABLE 11 INDICATIVE LIST OF PATENTS IN IHC MARKET
    5.10 REGULATORY ANALYSIS 
           5.10.1 US
                     TABLE 12 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
                     FIGURE 25 US: REGULATORY PROCESS FOR IVD DEVICES
           5.10.2 CANADA
                     FIGURE 26 CANADA: REGULATORY PROCESS FOR IVD DEVICES
           5.10.3 EUROPE
                     TABLE 13 EUROPE: CLASSIFICATION OF IVD DEVICES
                     FIGURE 27 EUROPE: REGULATORY PROCESS FOR IVD DEVICES
           5.10.4 JAPAN
                     FIGURE 28 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
                     TABLE 14 JAPAN: CLASSIFICATION OF IVD REAGENTS
                     TABLE 15 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.10.5 CHINA
                     TABLE 16 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.10.6 INDIA
                     FIGURE 29 INDIA: REGULATORY PROCESS FOR IVD DEVICES
           5.10.7 BRAZIL
                     FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
    5.11 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 17 IMPACT OF PORTER’S FIVE FORCES ANALYSIS ON IHC MARKET
           5.11.1 THREAT OF NEW ENTRANTS
           5.11.2 THREAT OF SUBSTITUTES
           5.11.3 BARGAINING POWER OF BUYERS
           5.11.4 BARGAINING POWER OF SUPPLIERS
           5.11.5 INTENSITY OF COMPETITIVE RIVALRY
    5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 
           TABLE 18 IMMUNOHISTOCHEMISTRY MARKET GROWTH: LIST OF CONFERENCES AND EVENTS
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 
           FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IMMUNOHISTOCHEMISTRY PRODUCTS
           FIGURE 32 BUYING CRITERIA FOR IMMUNOHISTOCHEMISTRY PRODUCTS
 
6 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW, BY PRODUCT (Page No. - 102)
    6.1 INTRODUCTION 
          TABLE 19 IMMUNOHISTOCHEMISTRY MARKET DEMAND, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 ANTIBODIES 
          TABLE 20 IMMUNOHISTOCHEMISTRY MARKET ANALYSIS FOR ANTIBODIES, BY REGION,  2021–2028 (USD MILLION)
          TABLE 21 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 22 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 23 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 24 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
           6.2.1 PRIMARY ANTIBODIES
                    6.2.1.1 Wide applications in diagnostics and research to support demand for primary antibodies
                                TABLE 25 IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 26 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 27 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 28 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES,  BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.2 SECONDARY ANTIBODIES
                    6.2.2.1 Signal amplification through conjugation and comparatively easy manufacturing to fuel market
                                TABLE 29 IMMUNOHISTOCHEMISTRY MARKET PREDICTION FOR SECONDARY ANTIBODIES, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 30 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 31 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 32 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES,  BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 REAGENTS 
          TABLE 33 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 34 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 35 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 36 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 37 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
           6.3.1 HISTOLOGICAL STAINS
                    6.3.1.1 Developments in concurrent detection of multiple antigenic sites and cancer disease progression studies to propel market
                                TABLE 38 IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 39 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 40 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 41 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS,  BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.2 BLOCKING SERA AND REAGENTS
                    6.3.2.1 Blocking sera and reagents to prevent nonspecific binding and reduce background noise & potentially false-positive results
                                TABLE 42 IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 43 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 44 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 45 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.3 CHROMOGENIC SUBSTRATES
                    6.3.3.1 Chromogenic substrates segment to register highest growth during forecast period
                                TABLE 46 IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 47 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 48 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 49 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES,  BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.4 FIXATION REAGENTS
                    6.3.4.1 North America projected to be largest market for fixation reagents
                                TABLE 50 IMMUNOHISTOCHEMISTRY MARKET SIZE FOR FIXATION REAGENTS, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 51 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 52 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 53 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS,  BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.5 DILUENTS
                    6.3.5.1 Need of diluents for preparation of antibody solutions to promote market growth
                                TABLE 54 IMMUNOHISTOCHEMISTRY MARKET DEMAND FOR DILUENTS, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 55 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 56 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 57 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY,  2021–2028 (USD MILLION)
           6.3.6 ORGANIC SOLVENTS
                    6.3.6.1 Organic solvents to prevent physical damage in specimens and improve clarity while visualizing tissue samples
                                TABLE 58 IMMUNOHISTOCHEMISTRY MARKET ANALYSIS FOR ORGANIC SOLVENTS, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 59 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 60 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 61 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS,  BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.7 PROTEOLYTIC ENZYMES
                    6.3.7.1 Proteolytic enzymes improve accessibility of target antibodies
                                TABLE 62 IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 63 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 64 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 65 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES,  BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.8 OTHER REAGENTS
                    TABLE 66 IMMUNOHISTOCHEMISTRY MARKET TRENDS FOR OTHER REAGENTS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 67 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 68 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY,  2021–2028 (USD MILLION)
                    TABLE 69 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY,  2021–2028 (USD MILLION)
    6.4 EQUIPMENT 
          TABLE 70 IMMUNOHISTOCHEMISTRY MARKET GROWTH FOR EQUIPMENT, BY REGION,  2021–2028 (USD MILLION)
          TABLE 71 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 72 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 73 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 74 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
           6.4.1 SLIDE-STAINING SYSTEMS
                    6.4.1.1 Development of high-throughput staining systems to  drive market growth
                                TABLE 75 IMMUNOHISTOCHEMISTRY MARKET PREDICTION FOR SLIDE-STAINING SYSTEMS, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 76 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 77 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 78 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS,  BY COUNTRY, 2021–2028 (USD MILLION)
           6.4.2 TISSUE PROCESSING SYSTEMS
                    6.4.2.1 Technological advancements and need for automation due to lack of skilled workforce to fuel market
                                TABLE 79 IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 80 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 81 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 82 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS,  BY COUNTRY, 2021–2028 (USD MILLION)
           6.4.3 SLIDE SCANNERS
                    6.4.3.1 Development of advanced multiplexed IHC scanners to drive market growth
                                TABLE 83 IMMUNOHISTOCHEMISTRY MARKET FORECAST FOR SLIDE SCANNERS, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 84 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 85 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2021–2028 USD MILLION)
                                TABLE 86 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY,  2021–2028 (USD MILLION)
           6.4.4 OTHER EQUIPMENT
                    TABLE 87 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 88 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 89 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 90 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
    6.5 KITS 
          TABLE 91 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 92 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 93 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 94 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 95 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION)
           6.5.1 HUMAN IMMUNOHISTOCHEMISTRY KITS
                    6.5.1.1 Increasing focus on cancer research to fuel market growth
                                TABLE 96 IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS,  BY REGION, 2021–2028 (USD MILLION)
                                TABLE 97 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 98 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 99 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY,  2021–2028 (USD MILLION)
           6.5.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS
                    6.5.2.1 Increasing preclinical drug testing to boost market
                                TABLE 100 IMMUNOHISTOCHEMISTRY MARKET DEMAND FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS,  BY REGION, 2021–2028 (USD MILLION)
                                TABLE 101 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 102 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 103 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY,  2021–2028 (USD MILLION)
 
7 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW, BY APPLICATION (Page No. - 149)
    7.1 INTRODUCTION 
          TABLE 104 IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2021–2028 (USD MILLION)
    7.2 DIAGNOSTIC APPLICATIONS 
          TABLE 105 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 106 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 107 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 108 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 109 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY DISEASE, 2021–2028 (USD MILLION)
           7.2.1 CANCER
                    7.2.1.1 Rise in incidence rate of cancer and growing use of IHC tests for cancer diagnostics to drive market
                                TABLE 110 COMMON CANCER MARKERS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
                                TABLE 111 IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 112 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 113 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
                                TABLE 114 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY,  2021–2028 (USD MILLION)
           7.2.2 INFECTIOUS DISEASES
                    7.2.2.1 Growing prevalence of infectious diseases and rising awareness of early diagnosis to propel market
                                TABLE 115 COMMON INFECTIOUS DISEASE MARKERS/ANTIGENS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
                                TABLE 116 IMMUNOHISTOCHEMISTRY MARKET SHARE FOR INFECTIOUS DISEASES, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 117 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 118 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 119 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
           7.2.3 NEPHROLOGICAL DISEASES
                    7.2.3.1 Wide application of IHC in transplant rejection expected to support market growth
                                TABLE 120 IMMUNOHISTOCHEMISTRY MARKET GROWTH FOR NEPHROLOGICAL DISEASES, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 121 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 122 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 123 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
           7.2.4 AUTOIMMUNE DISEASES
                    7.2.4.1 Availability of numerous primary antibodies and rapid processing of results to drive market
                                TABLE 124 IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 125 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 126 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 127 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
           7.2.5 NEUROLOGICAL DISEASES
                    7.2.5.1 Increasing global burden of neurological diseases to propel market growth
                                TABLE 128 COMMON IMMUNOHISTOCHEMISTRY MARKERS FOR CENTRAL NERVOUS SYSTEM
                                TABLE 129 IMMUNOHISTOCHEMISTRY MARKET DEMAND FOR NEUROLOGICAL DISEASES, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 130 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 131 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 132 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
           7.2.6 OTHER DISEASES
                    TABLE 133 IMMUNOHISTOCHEMISTRY MARKET ANALYSIS FOR OTHER DISEASES, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 134 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 135 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 136 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY,  2021–2028 (USD MILLION)
    7.3 RESEARCH APPLICATIONS 
          TABLE 137 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 138 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 139 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 140 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 141 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE,  2021–2028 (USD MILLION)
           7.3.1 DRUG DEVELOPMENT & TESTING
                    7.3.1.1 Quantitative image analysis makes IHC techniques ideal  for drug testing
                                TABLE 142 IMMUNOHISTOCHEMISTRY MARKET TRENDS FOR DRUG DEVELOPMENT & TESTING, BY REGION,  2021–2028 (USD MILLION)
                                TABLE 143 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 144 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING,  BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 145 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING,  BY COUNTRY, 2021–2028 (USD MILLION)
           7.3.2 OTHER RESEARCH APPLICATIONS
                    TABLE 146 IMMUNOHISTOCHEMISTRY MARKET PREDICTION FOR OTHER RESEARCH APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)
                    TABLE 147 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 148 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS,  BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 149 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 FORENSIC APPLICATIONS 
          TABLE 150 IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 151 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 152 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 153 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS,  BY COUNTRY, 2021–2028 (USD MILLION)
 
8 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW, BY END USER (Page No. - 179)
    8.1 INTRODUCTION 
          TABLE 154 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION)
    8.2 HOSPITALS & DIAGNOSTIC LABORATORIES 
           8.2.1 RISE IN SPECIALTY DIAGNOSTIC TESTS IN LABORATORIES AND IN-HOUSE DIAGNOSTIC PROCEDURES IN HOSPITALS TO DRIVE MARKET
                    TABLE 155 IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES,  BY REGION, 2021–2028 (USD MILLION)
                    TABLE 156 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 157 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 158 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 ACADEMIC & RESEARCH INSTITUTES 
           8.3.1 GROWING APPLICATION OF IHC TESTS FOR DRUG DEVELOPMENT STUDIES TO POSITIVELY IMPACT MARKET GROWTH
                    TABLE 159 IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY REGION, 2021–2028 (USD MILLION)
                    TABLE 160 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 161 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 162 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 OTHER END USERS 
          TABLE 163 IMMUNOHISTOCHEMISTRY MARKET GROWTH FOR OTHER END USERS, BY REGION,  2021–2028 (USD MILLION)
          TABLE 164 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,  BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 165 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 166 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY,  2021–2028 (USD MILLION)
 
9 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW, BY REGION (Page No. - 187)
    9.1 INTRODUCTION 
          TABLE 167 IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2021–2028 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 33 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT
          TABLE 168 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SEGMENTS, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 169 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
          TABLE 170 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 171 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 172 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 173 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 174 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SEGMENTATION, BY APPLICATION,  2021–2028 (USD MILLION)
          TABLE 175 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION)
          TABLE 176 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS,  BY TYPE, 2021–2028 (USD MILLION)
          TABLE 177 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.2.1 US
                    9.2.1.1 Availability of reimbursements for FDA-approved immunohistochemistry products to promote market
                                TABLE 178 RECENT DEVELOPMENTS IN US IHC MARKET
                                TABLE 179 US: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 180 US: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 181 US: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 182 US: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 183 US: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 184 US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 185 US: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION)
                                TABLE 186 US: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 187 US: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Rise in cancer cases in Canada to propel market growth
                                TABLE 188 CANADA: IMMUNOHISTOCHEMISTRY MARKET ANALYSIS, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 189 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 190 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 191 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 192 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 193 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 194 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY DISEASE, 2021–2028 (USD MILLION)
                                TABLE 195 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 196 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.2.3 NORTH AMERICA: RECESSION IMPACT
    9.3 EUROPE 
          TABLE 197 RECENT DEVELOPMENTS IN EUROPEAN IHC MARKET
          TABLE 198 EUROPE: IMMUNOHISTOCHEMISTRY MARKET DEMAND, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 199 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
          TABLE 200 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FORECAST FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 201 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 202 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 203 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 204 EUROPE: IMMUNOHISTOCHEMISTRY MARKET SEGMENTATION, BY APPLICATION,   2021–2028 (USD MILLION)
          TABLE 205 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY DISEASE, 2021–2028 (USD MILLION)
          TABLE 206 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 207 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Germany to dominate European IHC market due to vast research pool and favorable reimbursement policies
                                TABLE 208 GERMANY: IMMUNOHISTOCHEMISTRY MARKET SEGMENTS, BY PRODUCT,  2021–2028 (USD MILLION)
                                TABLE 209 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 210 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 211 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 212 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 213 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 214 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY DISEASE, 2021–2028 (USD MILLION)
                                TABLE 215 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 216 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.3.2 FRANCE
                    9.3.2.1 Increasing use of IHC in cancer diagnosis and research to drive market
                                TABLE 217 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 218 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 219 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 220 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 221 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 222 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 223 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY DISEASE, 2021–2028 (USD MILLION)
                                TABLE 224 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 225 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.3 UK
                    9.3.3.1 Increase in number of cancer research studies to support  market growth
                                TABLE 226 UK: IMMUNOHISTOCHEMISTRY MARKET PREDICTION, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 227 UK: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 228 UK: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 229 UK: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 230 UK: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 231 UK: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 232 UK: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION)
                                TABLE 233 UK: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 234 UK: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 High incidence of cancer and rising geriatric population to support market growth in Italy
                                TABLE 235 ITALY: IMMUNOHISTOCHEMISTRY MARKET SEGMENTS, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 236 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 237 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 238 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 239 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 240 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 241 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION)
                                TABLE 242 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 243 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Spike in demand for personalized medicine to drive demand for IHC tests to find potential biomarkers
                                TABLE 244 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 245 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 246 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 247 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 248 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 249 SPAIN: IMMUNOHISTOCHEMISTRY MARKET SEGMENTATION, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 250 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY DISEASE, 2021–2028 (USD MILLION)
                                TABLE 251 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 252 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 253 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                    TABLE 254 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 255 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 256 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 257 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 258 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                    TABLE 259 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY DISEASE, 2021–2028 (USD MILLION)
                    TABLE 260 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS,  BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 261 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.3.7 EUROPE: RECESSION IMPACT
    9.4 ASIA PACIFIC 
           FIGURE 34 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET TRENDS SNAPSHOT
           TABLE 262 RECENT DEVELOPMENTS IN ASIA PACIFIC IHC MARKET
           TABLE 263 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
           TABLE 264 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
           TABLE 265 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
           TABLE 266 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
           TABLE 267 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
           TABLE 268 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
           TABLE 269 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
           TABLE 270 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY DISEASE, 2021–2028 (USD MILLION)
           TABLE 271 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
           TABLE 272 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 Rise in product approvals and shift toward immunoassay diagnostics to fuel market growth
                                TABLE 273 CHINA: IMMUNOHISTOCHEMISTRY MARKET ANALYSIS, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 274 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 275 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 276 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 277 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 278 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 279 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY DISEASE, 2021–2028 (USD MILLION)
                                TABLE 280 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 281 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Advancing healthcare expenditure to drive market
                                TABLE 282 JAPAN: IMMUNOHISTOCHEMISTRY MARKET SEGMENTS, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 283 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 284 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 285 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 286 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 287 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 288 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY DISEASE, 2021–2028 (USD MILLION)
                                TABLE 289 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 290 JAPAN: IMMUNOHISTOCHEMISTRY MARKET SEGMENTATION, BY END USER, 2021–2028 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 High-end pathology and diagnostic services to propel market in India
                                TABLE 291 INDIA: IMMUNOHISTOCHEMISTRY MARKET PREDICTION, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 292 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 293 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 294 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 295 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 296 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 297 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY DISEASE, 2021–2028 (USD MILLION)
                                TABLE 298 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 299 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.4 AUSTRALIA
                    9.4.4.1 Investment initiatives to drive market growth
                                TABLE 300 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                                TABLE 301 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 302 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 303 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 304 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 305 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 306 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FORECAST FOR DIAGNOSTIC APPLICATIONS,  BY DISEASE, 2021–2028 (USD MILLION)
                                TABLE 307 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 308 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.5 SOUTH KOREA
                    9.4.5.1 Personalized medicine initiatives to fuel market growth
                                TABLE 309 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                TABLE 310 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 311 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 312 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 313 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 314 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 315 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY DISEASE, 2021–2028 (USD MILLION)
                                TABLE 316 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS,  BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 317 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.4.6 REST OF ASIA PACIFIC
                    TABLE 318 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                    TABLE 319 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 320 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 321 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 322 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 323 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                    TABLE 324 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION)
                    TABLE 325 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 326 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.4.7 ASIA PACIFIC: RECESSION IMPACT
    9.5 LATIN AMERICA 
           9.5.1 SPIKE IN INCIDENCE OF CANCER IN LATIN AMERICA TO BOOST MARKET
                    TABLE 327 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET SEGMENTS, BY PRODUCT,  2021–2028 (USD MILLION)
                    TABLE 328 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 329 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 330 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 331 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 332 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                    TABLE 333 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,  BY DISEASE, 2021–2028 (USD MILLION)
                    TABLE 334 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS,  BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 335 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.5.2 LATIN AMERICA: RECESSION IMPACT
    9.6 MIDDLE EAST & AFRICA 
           9.6.1 GOVERNMENT INITIATIVES FOCUSED ON BOOSTING HEALTHCARE INFRASTRUCTURE DEVELOPMENT TO DRIVE MARKET
                    TABLE 336 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
                    TABLE 337 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 338 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 339 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 340 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 341 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                    TABLE 342 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION)
                    TABLE 343 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 344 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
 
10 COMPETITIVE LANDSCAPE (Page No. - 276)
     10.1 OVERVIEW 
     10.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 
             FIGURE 35 IMMUNOHISTOCHEMISTRY MARKET: STRATEGIES ADOPTED BY KEY PLAYERS, 2020–2023
     10.3 MARKET SHARE ANALYSIS 
             FIGURE 36 IMMUNOHISTOCHEMISTRY MARKET: SHARE ANALYSIS OF KEY PLAYERS (2022)
     10.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 37 IMMUNOHISTOCHEMISTRY MARKET: REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS FOR PAST FIVE YEARS
     10.5 COMPANY EVALUATION QUADRANT 
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
                       FIGURE 38 IMMUNOHISTOCHEMISTRY MARKET FORECAST: COMPANY EVALUATION QUADRANT, 2022
     10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 STARTING BLOCKS
             10.6.3 RESPONSIVE COMPANIES
             10.6.4 DYNAMIC COMPANIES
                       FIGURE 39 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
     10.7 COMPANY PRODUCT FOOTPRINT 
             TABLE 345 IMMUNOHISTOCHEMISTRY MARKET: PRODUCT PORTFOLIO ANALYSIS (2022)
     10.8 COMPANY REGIONAL FOOTPRINT 
             TABLE 346 IMMUNOHISTOCHEMISTRY MARKET: REGIONAL REVENUE MIX (2022)
     10.9 COMPETITIVE BENCHMARKING OF START-UPS/SMES 
             TABLE 347 IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF KEY START-UPS/SMES
     10.10 COMPETITIVE SCENARIO 
             TABLE 348 IMMUNOHISTOCHEMISTRY MARKET TRENDS: PRODUCT LAUNCHES, JANUARY 2020–MAY 2023
             TABLE 349 IMMUNOHISTOCHEMISTRY MARKET: DEALS, JANUARY 2020–MAY 2023
             TABLE 350 IMMUNOHISTOCHEMISTRY MARKET: OTHER DEVELOPMENTS, JANUARY 2020–MAY 2023
 
11 COMPANY PROFILES (Page No. - 290)
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
     11.1 KEY PLAYERS 
             11.1.1 F. HOFFMANN-LA ROCHE AG
                        TABLE 351 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
                        FIGURE 40 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2022)
             11.1.2 DANAHER CORPORATION
                        TABLE 352 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             11.1.3 AGILENT TECHNOLOGIES, INC.
                        TABLE 353 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
             11.1.4 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 354 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
             11.1.5 MERCK KGAA
                        TABLE 355 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 44 MERCK KGAA: COMPANY SNAPSHOT (2022)
             11.1.6 BIO-RAD LABORATORIES, INC.
                        TABLE 356 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
             11.1.7 BIO-TECHNE CORPORATION
                        TABLE 357 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
                        FIGURE 46 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2022)
             11.1.8 ABCAM PLC
                        TABLE 358 ABCAM PLC: BUSINESS OVERVIEW
                        FIGURE 47 ABCAM PLC: COMPANY SNAPSHOT (2022)
             11.1.9 BECTON, DICKINSON AND COMPANY
                        TABLE 359 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
             11.1.10 PERKINELMER, INC.
                        TABLE 360 PERKINELMER, INC.: BUSINESS OVERVIEW
                        FIGURE 49 PERKINELMER, INC.: COMPANY SNAPSHOT (2022)
             11.1.11 TAKARA BIO, INC.
                        TABLE 361 TAKARA BIO, INC.: BUSINESS OVERVIEW
                        FIGURE 50 TAKARA BIO, INC.: COMPANY SNAPSHOT (2022)
             11.1.12 PHC HOLDINGS CORPORATION
                        TABLE 362 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 51 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
             11.1.13 CELL SIGNALING TECHNOLOGY, INC.
                        TABLE 363 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
             11.1.14 BIO SB, INC.
                        TABLE 364 BIO SB, INC.: BUSINESS OVERVIEW
             11.1.15 MILTENYI BIOTEC
                        TABLE 365 MILTENYI BIOTEC: BUSINESS OVERVIEW
             11.1.16 SAKURA FINETEK JAPAN CO., LTD.
                        TABLE 366 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW
             11.1.17 ENZO BIOCHEM, INC.
                        TABLE 367 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW
                        FIGURE 52 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2022)
             11.1.18 ORIGENE TECHNOLOGIES, INC.
                        TABLE 368 ORIGENE TECHNOLOGIES, INC.: BUSINESS OVERVIEW
     11.2 OTHER PLAYERS 
             11.2.1 EAGLE BIOSCIENCES, INC.
                        TABLE 369 EAGLE BIOSCIENCES, INC.: BUSINESS OVERVIEW
             11.2.2 BIOCARE MEDICAL, LLC
                        TABLE 370 BIOCARE MEDICAL, LLC: BUSINESS OVERVIEW
             11.2.3 ELABSCIENCE BIOTECHNOLOGY, INC.
                        TABLE 371 ELABSCIENCE BIOTECHNOLOGY, INC.: COMPANY OVERVIEW
             11.2.4 BIOGENEX LABORATORIES
                        TABLE 372 BIOGENEX LABORATORIES: COMPANY OVERVIEW
             11.2.5 DIAGNOSTIC BIOSYSTEMS, INC.
                        TABLE 373 DIAGNOSTIC BIOSYSTEMS, INC.: BUSINESS OVERVIEW
             11.2.6 HISTO-LINE LABORATORIES
                        TABLE 374 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW
             11.2.7 ROCKLAND IMMUNOCHEMICALS, INC.
                        TABLE 375 ROCKLAND IMMUNOCHEMICALS, INC.: BUSINESS OVERVIEW
             11.2.8 GENEMED BIOTECHNOLOGIES, INC.
                        TABLE 376 GENEMED BIOTECHNOLOGIES, INC.: BUSINESS OVERVIEW
             11.2.9 CANDOR BIOSCIENCE GMBH
                        TABLE 377 CANDOR BIOSCIENCE GMBH: BUSINESS OVERVIEW
 
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
 
12 APPENDIX (Page No. - 407)
     12.1 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     12.2 CUSTOMIZATION OPTIONS 
     12.3 RELATED REPORTS 
     12.4 AUTHOR DETAILS 

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global Immunohistochemistry market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from government sources [such as the World Bank, World Health Organization (WHO), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Centre for Biotechnology Information (NCBI), Therapeutic Goods Administration (TGA), and Centers for Disease Control and Prevention (CDC)]; sites like ClinicalTrials.gov, fiercebiotech, and annual reports; SEC filings; press releases; investor presentations; journals; expert interviews; MarketsandMarkets analysis; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global immunohistochemistry market, which was validated through primary research.

Primary Research

After acquiring basic knowledge about the global immunohistochemistry market scenario through secondary research, extensive primary research was conducted. Several primary interviews were conducted with market experts from both the OEMs and supply and the demand side participants (such as clinical diagnostic laboratories, hospitals, etc. ) across four major regions—North America, Europe, the Asia Pacific, and the Rest of the World. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews. The following is a breakdown of the primary respondents:

The following is a breakdown of the primary respondents:

Immunohistochemistry Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the immunohistochemistry market was estimated through different approaches. A detailed market estimation approach was followed to estimate and validate the global market value and other dependent submarkets, as mentioned below. Both top-down and bottom-up approaches were used to estimate and validate the total size of the biosimilars market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the immunohistochemistry business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Approach 1: Company Revenue Analysis (Bottom-Up Approach)

  • Revenues for individual companies were gathered from public sources and databases.
  • The IHC business share of leading players was gathered from secondary sources to the extent available. In certain cases, the share of IHC product businesses was ascertained through a detailed analysis of various parameters, including product portfolios and market positioning.
  • Individual share or revenue estimates were validated through expert interviews.

Immunohistochemistry Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Market Definition:

Immunohistochemistry (IHC) is a laboratory test that uses antibodies to test certain antigens in a tissue, combining immunological, anatomical, and biochemical techniques. There are multiple approaches and permutations in immunohistochemistry applicable for drug testing and the diagnosis of chronic diseases, such as cancer, infectious diseases, cardiovascular diseases, diabetes, and autoimmune diseases.

Key Stakeholders

  • Manufacturers and Distributors of Immunohistochemistry Products
  • Third-party Suppliers of Immunohistochemistry Products
  • Contract Research Organizations
  • Market Research and Consulting Firms
  • R&D Centers and Institutes
  • Hospitals and Clinics
  • Academic Institutions
  • Diagnostic Laboratories

Report Objectives

  • To define, describe, and forecast the Immunohistochemistry market by product, application, end user, and region.
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges).
  • To strategically analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the size of market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific (APAC), Latin America, and the Middle East & Africa.
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies.
  • To track and analyze competitive developments such as acquisitions, collaborations, and product launches in the Immunohistochemistry market.
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographic Analysis

  • Further breakdown of the European immunohistochemistry market into countries from the Rest of Europe.
  • Further breakdown of the Asia Pacific immunohistochemistry market into countries from the Rest of the APAC.
  • Further breakdown of the Latin America immunohistochemistry market into Brazil, Mexico, and the Rest of Latin America.

Company Information

Detailed analysis and profiling of additional market players (up to 5), inclusive of:

  • Business Overview
  • Financial Information
  • Product Portfolio
  • Developments (Last Three Years)
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 4780
Published ON
Jun, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Immunohistochemistry (IHC) Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback